John Dawson appointed Senior Independent Director

RNS Number : 3547I

Ergomed plc

02 December 2022

 

 PRESS RELEASE

John Dawson CBE Appointed Senior Independent Director

Guildford, UK - 2 December 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has been appointed Senior Independent Director of the Board with immediate effect. Mr Dawson has served as an independent Non-Executive Director and Chair of the Audit Committee of the Ergomed Board of Directors since March 2022.

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer) Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Advisor and Joint Broker)	Tel: [phone]
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP (Joint Broker) James Steel / Dr Christopher Golden	Tel: [phone]
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Matthew Neal	[e-mail]
Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

 

END

 

 

BOATBBBTMTTMTMT